Scholarlink

Background <p>Rheumatoid arthritis is a chronic, inflammatory, and symmetrical peripheral polyarthritis often associated with extra-articular manifestations, that end in marked functional impairment. Chemokines, such as monocyte chemotactic protein-1, are not only potential therapeutic targets but also play a crucial role in leukocyte migration within chronic inflammatory diseases. This migration contributes to synovitis and ultimately plays a critical role in the pathogenesis of rheumatoid arthritis. The purpose of this study was to evaluate monocyte chemotactic factor-1 serum levels and its association with RA disease activity score 28. This cross-sectional study included 306 patients aged 18–80&#xa0;years. Clinical arthritic activity was assessed using swollen joint count, tender joint count, and disease activity score 28, while monocyte chemotactic protein-1, erythrocyte sedimentation rate, or C-reactive protein were used as laboratory biomarkers.</p> Results <p>The mean age of the patients was 53.7 ± 13.6&#xa0;years, with a female predominance (191/306, 63%). Monocyte chemotactic protein-1correlated with clinical and radiographic parameters of disease activity &amp; progression, whereas C-reactive protein and erythrocyte sedimentation rate correlated with all clinical parameters except tender joint count. Disease activity score 28 monocyte chemotactic protein-1 showed a significant correlation with Disease Activity Score 28 C-reactive protein (r = 0.678) and Disease Activity Score 28 erythrocyte sedimentation rate (r = 0.311) after one year. Disease activity score 28 monocyte chemotactic protein-1 showed a highly significant association with predictive progression (AUC = 0.926).</p> Conclusion <p>The findings of this study suggest that Disease Activity Score 28 and monocyte chemotactic protein-1 may serve as reliable clinical indicators to assess rheumatoid arthritis disease activity and monitor its progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cross link between monocyte chemotactic protein-1 and rheumatoid arthritis activity and progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Alaa El-Salawy,
  • Souzan Gado,
  • Hanaa El-Banna

摘要

Background

Rheumatoid arthritis is a chronic, inflammatory, and symmetrical peripheral polyarthritis often associated with extra-articular manifestations, that end in marked functional impairment. Chemokines, such as monocyte chemotactic protein-1, are not only potential therapeutic targets but also play a crucial role in leukocyte migration within chronic inflammatory diseases. This migration contributes to synovitis and ultimately plays a critical role in the pathogenesis of rheumatoid arthritis. The purpose of this study was to evaluate monocyte chemotactic factor-1 serum levels and its association with RA disease activity score 28. This cross-sectional study included 306 patients aged 18–80 years. Clinical arthritic activity was assessed using swollen joint count, tender joint count, and disease activity score 28, while monocyte chemotactic protein-1, erythrocyte sedimentation rate, or C-reactive protein were used as laboratory biomarkers.

Results

The mean age of the patients was 53.7 ± 13.6 years, with a female predominance (191/306, 63%). Monocyte chemotactic protein-1correlated with clinical and radiographic parameters of disease activity & progression, whereas C-reactive protein and erythrocyte sedimentation rate correlated with all clinical parameters except tender joint count. Disease activity score 28 monocyte chemotactic protein-1 showed a significant correlation with Disease Activity Score 28 C-reactive protein (r = 0.678) and Disease Activity Score 28 erythrocyte sedimentation rate (r = 0.311) after one year. Disease activity score 28 monocyte chemotactic protein-1 showed a highly significant association with predictive progression (AUC = 0.926).

Conclusion

The findings of this study suggest that Disease Activity Score 28 and monocyte chemotactic protein-1 may serve as reliable clinical indicators to assess rheumatoid arthritis disease activity and monitor its progression.